Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CYBN Stock Forecast 2026-2027
$5.24
Current Price
$261.45M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CYBN Price Targets
+1,022.8%
To High Target of $58.83
+836.1%
To Median Target of $49.05
+491.3%
To Low Target of $30.99
CYBN Price Momentum
+2.3%
1 Week Change
-8.7%
1 Month Change
-8.7%
1 Year Change
-35.9%
Year-to-Date Change
-46.7%
From 52W High of $9.83
+22.1%
From 52W Low of $4.29
📊 TOP ANALYST CALLS
Did CYBN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Cybin is one of their latest high-conviction picks.
Latest CYBN Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, CYBN has a bullish consensus with a median price target of $49.05 (ranging from $30.99 to $58.83). The overall analyst rating is N/A (N/A/10). Currently trading at $5.24, the median forecast implies a 836.1% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CYBN Analyst Ratings
7
Buy
0
Hold
0
Sell
CYBN Price Target Range
Low
$30.99
Average
$49.05
High
$58.83
Current: $5.24
Latest CYBN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CYBN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2025 | Guggenheim | Buy | Maintains | $N/A | |
| Nov 20, 2025 | Canaccord Genuity | Sumant Kulkarni | Buy | Maintains | $45.00 |
| Nov 14, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jul 8, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 13, 2025 | Guggenheim | Buy | Initiates | $N/A | |
| Feb 13, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 12, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Jan 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 19, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 19, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Nov 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Sep 23, 2024 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Aug 23, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 31, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jul 31, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $N/A |
| Jun 21, 2024 | Cantor Fitzgerald | Charles Duncan | Overweight | Reiterates | $N/A |
| May 16, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 13, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 19, 2021 | Maxim Group | Jason McCarthy | Hold | Downgrade | $N/A |
Cybin Inc. (CYBN) Competitors
The following stocks are similar to Cybin based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Cybin Inc. (CYBN) Financial Data
Cybin Inc. has a market capitalization of $261.45M with a P/E ratio of -0.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -53.0%.
Valuation Metrics
Market Cap
$261.45M
Enterprise Value
$330.82M
P/E Ratio
-0.9x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+32.0%
Current Ratio
8.6x
Debt/Equity
20.8x
ROE
-53.0%
ROA
-32.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Cybin Inc. (CYBN) Business Model
About Cybin Inc.
What They Do
Develops psychedelic therapeutics for mental health.
Business Model
Cybin Inc. generates revenue by developing innovative drug candidates derived from psilocybin and other psychoactive compounds aimed at treating neuropsychiatric disorders. The company focuses on creating new formulations and delivery methods to improve the efficacy and safety of its therapeutic products.
Additional Information
Operating in the biopharmaceutical sector, Cybin is positioned within the growing field of mental health and psychedelics, attracting significant investor interest. The company's stock is traded on various exchanges, including a secondary listing on the Berlin Stock Exchange, which enhances its visibility and access to European capital markets.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
50
CEO
Mr. Eric So L.L.B.
Country
Canada
IPO Year
2019
Website
cybin.comCybin Inc. (CYBN) Latest News & Analysis
Latest News
Frequently Asked Questions About CYBN Stock
What is Cybin Inc.'s (CYBN) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Cybin Inc. (CYBN) has a median price target of $49.05. The highest price target is $58.83 and the lowest is $30.99.
Is CYBN stock a good investment in 2026?
According to current analyst ratings, CYBN has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CYBN stock?
Wall Street analysts predict CYBN stock could reach $49.05 in the next 12 months. This represents a 836.1% increase from the current price of $5.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Cybin Inc.'s business model?
Cybin Inc. generates revenue by developing innovative drug candidates derived from psilocybin and other psychoactive compounds aimed at treating neuropsychiatric disorders. The company focuses on creating new formulations and delivery methods to improve the efficacy and safety of its therapeutic products.
What is the highest forecasted price for CYBN Cybin Inc.?
The highest price target for CYBN is $58.83 from at , which represents a 1,022.8% increase from the current price of $5.24.
What is the lowest forecasted price for CYBN Cybin Inc.?
The lowest price target for CYBN is $30.99 from at , which represents a 491.3% increase from the current price of $5.24.
What is the overall CYBN consensus from analysts for Cybin Inc.?
The overall analyst consensus for CYBN is bullish. Out of 4 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $49.05.
How accurate are CYBN stock price projections?
Stock price projections, including those for Cybin Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 10, 2026 6:24 AM UTC